Prothena Corporation plc: Prothena Presents New Preclinical

Data from oral presentation adds to growing body of evidence supporting the profile of PRX012, which is designed to target all aggregated forms of amyloid beta with high binding potency Demonstrated

Related Keywords

Gothenburg , Vastra Gotalands Lan , Sweden , Michael Bachner , Wagner Zago , International Conference On Alzheimer , Corporate Communications , Prothena Corporation , Forum Discussions , Company On Twitter Prothenacorp , Exchange Commission , Nasdaq , Plasmon Resonance , Chief Scientific Officer , Prothena Activities , Disease Modifying Treatments , Taking Stock , Two Forum Discussions , From Basics , Anti Tau Therapies , Clinical Trials , Annual Report , Senior Director , Prothena , Corporation , Presents , Reclinical , Data , Supporting , Pest , Glass , Profile , Rx012 , Text , Generation , Anti , Amyloid , Meta , Ntibody , 023 ,